ERRATUM**Reining in the oversized Phase I cancer trial***Asher Mullard**Nature Reviews Drug Discovery* **15**, 371–373 (2016)

Vemurafenib was misidentified as an ALK inhibitor, but the article has now been corrected to indicate that the drug is a BRAF inhibitor.